In brain tumor, CaMKK2 was upregulated in neurons and TAMs, and deficiency of CaMKK2 reprogrammed tumor-promoting TAMs to an immunostimulatory phenotype, improving the efficiency of immunotherapy [109]. This evidence concerns the gene CAMKK2 and brain neoplasm.